Sanofi (SAN) PT Set at €83.00 by Kepler Capital Markets
SAN has been the subject of several other reports. Goldman Sachs Group set a €82.00 ($101.23) price objective on shares of Sanofi and gave the stock a neutral rating in a report on Friday, November 3rd. Morgan Stanley set a €92.00 ($113.58) price objective on shares of Sanofi and gave the stock a buy rating in a report on Thursday, October 26th. Berenberg Bank set a €97.00 ($119.75) price objective on shares of Sanofi and gave the stock a neutral rating in a report on Monday, January 22nd. Deutsche Bank set a €93.00 ($114.81) price objective on shares of Sanofi and gave the stock a buy rating in a report on Friday, January 19th. Finally, Barclays set a €65.00 ($80.25) price objective on shares of Sanofi and gave the stock a sell rating in a report on Tuesday, January 23rd. One analyst has rated the stock with a sell rating, ten have given a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of Hold and an average target price of €85.50 ($105.56).
Shares of Sanofi (EPA SAN) opened at €66.69 ($82.33) on Tuesday. The stock has a market cap of $84,240.00 and a price-to-earnings ratio of 18.47. Sanofi has a 1-year low of €65.88 ($81.33) and a 1-year high of €92.97 ($114.78).
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.